公开(公告)号：US20200215001A1

公开(公告)日：2020-07-09

申请号：US16822466

申请日：2020-03-18

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley ,  Michael R. Vasko

IPC分类号： A61K31/122 ,  A61K31/12 ,  C07C66/00 ,  C07C235/78 ,  C07D295/185 ,  A61K31/16 ,  A61K31/165 ,  A61K31/19 ,  A61K31/192 ,  A61K31/20 ,  A61K31/21 ,  A61K31/495 ,  A61K31/5375

摘要： Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.

公开(公告)号：US20190117602A1

公开(公告)日：2019-04-25

申请号：US16092816

申请日：2018-04-16

申请人： INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

发明人： Mark R. Kelley ,  Jill Fehrenbacher

IPC分类号： A61K31/192 ,  A61P25/02 ,  A61N5/00

摘要： Methods of reducing neuronal sensitivity, thereby reducing inflammation and chronic pain, are disclosed herein. Particularly disclosed are methods of administrating the apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE1/Ref-1) inhibitor, APX3330, to enhance the DNA base excision repair (BER) pathway, thereby reducing neuronal sensitivity to inflammatory mediators and alleviating inflammatory or chronic pain.

公开(公告)号：US20220184016A1

公开(公告)日：2022-06-16

申请号：US17688081

申请日：2022-03-07

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley

IPC分类号： A61K31/201 ,  A61K31/203 ,  A61K31/454 ,  A61K31/198 ,  A61K31/7068 ,  A61K33/243 ,  A61K31/122 ,  A61K31/13 ,  A61K31/195 ,  A61K31/282 ,  A61K45/06 ,  A61K39/395

摘要： Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.

公开(公告)号：US20210038553A1

公开(公告)日：2021-02-11

申请号：US17026671

申请日：2020-09-21

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley ,  Melissa L. Fishel

IPC分类号： A61K31/201 ,  A61K31/165 ,  A61K31/343 ,  A61K31/501 ,  A61K31/519 ,  A61K31/7068 ,  A61K31/713 ,  A61K33/24 ,  A61K45/06 ,  A61K31/337 ,  A61K31/192 ,  A61P35/00 ,  A61K33/243 ,  A61K31/18 ,  A61K31/20 ,  A61K31/282

摘要： Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).

公开(公告)号：US20190274988A1

公开(公告)日：2019-09-12

申请号：US16418276

申请日：2019-05-21

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley

IPC分类号： A61K31/201 ,  A61K33/24 ,  A61K31/7068 ,  A61K31/198 ,  A61K31/454 ,  A61K31/203 ,  A61K31/122 ,  A61K45/06 ,  A61K31/282 ,  A61K31/195 ,  A61K31/13 ,  A61K39/395

摘要： Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present disclosure describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.

公开(公告)号：US10154973B2

公开(公告)日：2018-12-18

申请号：US15868245

申请日：2018-01-11

申请人： Indiana University Research and Technology Corporation ,  Apexian Pharmaceuticals, Inc.

发明人： Mark R. Kelley ,  James H. Wikel

IPC分类号： C07D295/185 ,  C07D295/192 ,  C07C235/78 ,  C07D211/76 ,  C07C259/06 ,  A61K31/165 ,  A61K31/185 ,  A61K31/45 ,  A61K31/495 ,  A61K31/5375

摘要： The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.

公开(公告)号：US09315481B2

公开(公告)日：2016-04-19

申请号：US14384814

申请日：2013-03-13

申请人： INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

发明人： Mark R. Kelley ,  Melissa L. Fishel ,  Angelo A. Cardoso

IPC分类号： A61K31/535 ,  C07D295/192 ,  A61K45/06 ,  A61K31/16 ,  A61K31/164 ,  A61K31/201 ,  A61K31/381 ,  A61K31/45 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/573 ,  A61K31/704 ,  C07C49/563 ,  C07C59/90 ,  C07C235/78 ,  C07D211/40

CPC分类号： C07D295/192 ,  A61K31/16 ,  A61K31/164 ,  A61K31/201 ,  A61K31/381 ,  A61K31/45 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/573 ,  A61K31/704 ,  A61K45/06 ,  C07C49/563 ,  C07C59/90 ,  C07C235/78 ,  C07D211/40 ,  A61K2300/00

摘要： Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (ALL) in its various forms.

摘要翻译： 化合物，化合物的方法和用途及其药物组合物在本文中描述用于治疗白血病。 特别地，本文描述了化合物，化合物的方法和用途及其药物组合物，用于治疗其各种形式的急性淋巴细胞性白血病（ALL）。

公开(公告)号：US20220062205A1

公开(公告)日：2022-03-03

申请号：US17415065

申请日：2019-12-11

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley ,  Kulmira Nurgali

IPC分类号： A61K31/165 ,  A61K45/06 ,  A61P29/00

摘要： Methods of reducing inflammation and chronic pain in the gut of a subject suffering from inflammatory bowel disease (IBD) are disclosed herein. Particularly disclosed are methods of administrating the apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE1/Ref-1) inhibitor, APX3330, which blocks APE1 and regulates transcription factors (TFs) involved in inflammation, thereby alleviating inflammatory or chronic pain.

公开(公告)号：US10772859B2

公开(公告)日：2020-09-15

申请号：US15575519

申请日：2016-05-05

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley ,  Melissa Fishel

IPC分类号： A61K31/192 ,  A61K45/06 ,  A61K31/519 ,  A61K31/63 ,  A61P35/00

摘要： Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APE1/Ref-1) are disclosed. More particularly, methods for inhibiting APE1/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.

公开(公告)号：US20190350885A1

公开(公告)日：2019-11-21

申请号：US16480010

申请日：2018-01-18

申请人： Indiana University Research and Technology Corporation

发明人： Mark R. Kelley ,  Reuben Kapur

IPC分类号： A61K31/192

摘要： Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating myeloid malignancies. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), and/or myelodysplastic syndrome (MDS).